FDA May Not Pursue Genetic Label Changes 'As Aggressively' as Before; Hopes to Focus on Biomarkers Instead | GenomeWeb
NEW YORK (GenomeWeb News) — The US Food and Drug Administration “might not” pursue genetic label changes “as aggressively as it had in the past,” and instead hopes to focus more on how biomarkers affect drug safety and efficacy, according to a senior FDA official.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.